ERBB2 and cancer: Anastrozole reduced incidence of invasive HER2-negative cancers by 43% (HR 0·57, 95% CI 0·41–0·78), which was similar to that for invasive HER2-positive cancers (0·52, 0·23–1·17; appendix p 2).